CompoAtlas

METABOLIC ORAL CAPSULES

Food supplement declared in France, declaration No 2024-5-967, decision dated 22 May 2024

METABOLIC ORAL CAPSULES (ELANCYL) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
ELANCYL
Food business operator placing the product on the market
LABORATOIRE DERMATOLOGIQUE ACM
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Capsule
Daily dose
2 gelules par jour
Not recommended for (according to the manufacturer)
Femmes enceintes

Declaration 141938, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Trigonella foenum-graecum L.GraineExtrait sec aqueux45 mg
Capsicum annuum L.FruitExtrait sec alcoolique30 mg

Other active ingredients

NamePer day
Glucomannanenot declared
Protéine de sojanot declared
Hespéridinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Sulfate de zincZinc25 mg15 mg

Additives

E460, E414, E322, E553b, E464, E141, E341, E516

Other ingredients

eau

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Réservé à l'adulte, déconseillé pour les femmes enceintes et allaitantes

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Trigonella foenum-graecum L.
    Read the warning, when it applies and the studies cited

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 29 May 2026

  • Capsicum annuum L.
    Read the warning, when it applies and the studies cited

    CAYENNE - CAPSICUM ANNUUM Oral

    Cautions and warnings

    Condition of application: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

  • Glucomannane
    Read the warning, when it applies and the studies cited

    GLUCOMANNAN

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (UpToDate 2023; EMA 2013; Chen et al. 2003; Vuksan et al. 2001).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Laxative; Promotion of bowel movement; Constipation relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: All products.

    Do not use if you have difficulty swallowing (FDA 2023; Sweetman 2007; Vanderbeek et al. 2007; Henry et al. 1986).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2013; Pray 2006; Berardi et al. 2002).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience temporary gas and bloating (Sood et al. 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : ELANCYL

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line